|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.80 SEK | -1.78% |
|
+2.96% | -16.81% |
| 08-06 | SynAct Pharma Secures Appellate Board Backing in US Patent Application | MT |
| 08-05 | Buy rating lifted Nederman, OMXS30 index unchanged | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 111M | - | - | - | - | - |
| 1,057B | |||||
| 625B | - | - | - | ||
| 435B | |||||
| 363B | |||||
| 296B |
- Stock Market
- Stocks
- SYNACT Stock
- Charts SynAct Pharma AB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
